Triplex

Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1

Retrieved on: 
Monday, October 16, 2023

MIAMI, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Helocyte, Inc. (“Helocyte”), a subsidiary company of Fortress Biotech, Inc. (“Fortress”) (Nasdaq: FBIO), today announced that it executed an exclusive option agreement with City of Hope for patent rights to use Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus (“CMV”)-specific, Anti-Human Immunodeficiency Virus (“HIV”) Chimeric Antigen Receptor (“CAR”) (collectively, CMV/HIV-CAR) T Cells for the treatment of adults living with HIV. Triplex was initially developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.

Key Points: 
  • Triplex was initially developed by City of Hope , one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.
  • Additionally, the California Institute for Regenerative Medicine (“CIRM”) recently awarded a $11.3 million grant to City of Hope to fund a Phase 1 clinical trial.
  • The trial will initially enroll at City of Hope and University of California at San Diego.
  • The study illustrated the potential long-term durability of the combination therapy, which induced therapeutic immune cells to take hold in bone marrow.

Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program

Retrieved on: 
Thursday, June 15, 2023

MIAMI, June 15, 2023 (GLOBE NEWSWIRE) -- Helocyte, Inc. (“Helocyte”), a subsidiary company of Fortress Biotech, Inc. (Nasdaq: FBIO), today announced that the National Cancer Institute (“NCI”) has awarded a $3.22 million grant to City of Hope for clinical studies of Triplex, a cytomegalovirus (“CMV”) vaccine being developed by Helocyte and City of Hope. This competitive award will fund two planned multicenter, placebo-controlled, randomized Phase 2 studies to evaluate the potential safety and immunological response of Triplex and its ability to enhance CMV-specific T cell immunity in stem cell donors to reduce the risk of CMV events in recipients of allogeneic hematopoietic cell transplant (“HCT”). Triplex was initially developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.

Key Points: 
  • Triplex was initially developed by City of Hope , one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.
  • Diamond and his team developed Triplex and he serves as a consultant to Helocyte.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
  • Helocyte will provide clinical materials to support the trial.

Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, May 15, 2023

MIAMI, May 15, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.

Key Points: 
  • In March 2023, the FDA accepted the BLA filing for cosibelimab and set a PDUFA goal date of January 3, 2024.
  • Journey Medical’s total product net revenues were $12.2 million for the first quarter of 2023, compared to first quarter 2022 total product net revenues of $20.8 million.
  • On a non-GAAP basis, Fortress research and development expenses were $2.3 million for the first quarter of 2023, compared to $2.8 million for first quarter of 2022.
  • On a non-GAAP basis, Fortress selling, general and administrative expenses were $7.0 million, for the first quarter of 2023, compared to $6.2 million for the first quarter of 2022.

Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Retrieved on: 
Thursday, February 16, 2023

MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Helocyte, Inc., (“Helocyte”) a subsidiary company of Fortress Biotech, Inc. (Nasdaq: FBIO), announced today that data from a Phase 1 pilot trial (see NCT03560752) evaluating the potential safety, immunological response and efficacy of the cytomegalovirus (“CMV”) vaccine Triplex to enhance CMV protective immunity in immunosuppressed recipients of allogeneic hematopoietic cell transplants (“HCT”) will be presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (“Tandem Meetings”), taking place February 15-19, 2023, in Orlando, Florida. Triplex was developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015.

Key Points: 
  • City of Hope researchers led a pilot trial to explore the vaccination of immunocompetent HCT donors with Triplex to enhance CMV protective immunity in recipients of an allogeneic HCT.
  • “CMV is still the most common infectious complication in allogeneic HCT and remains of fundamental clinical concern.
  • Triplex was generally well-tolerated in stem cell donors who participated in the study with no serious adverse events reported.
  • All HCT recipients were fully engrafted with stem cells of donor origin without delay.

Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex

Retrieved on: 
Wednesday, February 15, 2023

MIAMI, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Helocyte, Inc., (“Helocyte”) a subsidiary company of Fortress Biotech, Inc. (Nasdaq: FBIO), announced today that data from a Phase 1 pilot study published in the American Journal of Hematology demonstrated the feasibility, safety, immunological response and potential efficacy associated with vaccination of a hematopoietic cell transplant (“HCT”) donor with the cytomegalovirus (“CMV”) vaccine Triplex to enhance protective CMV-specific T cells in immunosuppressed recipients of allogeneic HCT.

Key Points: 
  • The investigator-initiated trial conducted at City of Hope analyzed the results of 17 CMV-seropositive recipients who received an HCT from a matched related donor (“MRD”) vaccinated with Triplex prior to stem cell harvest and transplant.
  • Triplex was well tolerated with limited adverse events in donors and recipients, all of whom experienced successful engraftment.
  • This strategy has been shown to significantly enhance protective T and B cell responses and enhanced the immunogenicity associated with vaccination post-HSCT.
  • CMV reactivation requiring preemptive therapy in recipients with Triplex vaccinated donors (18%) was observed to be lower than those in similar cohorts prophylactically treated with letermovir (37%).

Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation

Retrieved on: 
Thursday, August 11, 2022

This competitive award will fund a multi-center, placebo-controlled, randomized Phase 2 study of Triplex for control of CMV in patients undergoing liver transplantation.

Key Points: 
  • This competitive award will fund a multi-center, placebo-controlled, randomized Phase 2 study of Triplex for control of CMV in patients undergoing liver transplantation.
  • Triplex was developed by City of Hope, one of the largest cancer research and treatment organizations in the United States.
  • Helocyte secured an exclusive worldwide license to Triplex from City of Hope in 2015.
  • The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Wan Bridge Brings Unique Lifestyle to Balmoral by Building First Build-to-Rent Homes in the Lagoon Community

Retrieved on: 
Monday, August 31, 2020

Wan Bridges Clearwater at Balmoral will be an upscale duplex and triplex community with 94 units ranging from 1,400 to 1,800 square feet with three to four bedrooms each.

Key Points: 
  • Wan Bridges Clearwater at Balmoral will be an upscale duplex and triplex community with 94 units ranging from 1,400 to 1,800 square feet with three to four bedrooms each.
  • Our product offers flexibility at a time of change in the home-building industry, said Kevin Stuckey, Senior Vice President of Development for Wan Bridge.
  • Wan Bridge currently owns and operates ten build-to-rent communities throughout Dallas and Houston and has plans to continue its reach across Texas.
  • By offering the build-to-rent alternative WB meets the increasing lifestyle demand by "Building the Future of Fine Living".

Ontic Signs License Agreement With Meggitt PLC

Retrieved on: 
Thursday, January 9, 2020

Ontic Engineering and Manufacturing, Inc. (Ontic), the aerospace industrys leading provider of Extended Life Solutions for Original Equipment Manufacturer (OEM) legacy products, has signed another new exclusive license agreement with Meggitt PLC for Pneumatic Valves, Digital Analogue Units (DAU), Triplex Transducer Units (TTU), Data Acquisition and Processing Units (DAPU) and Electronic Processing Units (EPU).

Key Points: 
  • Ontic Engineering and Manufacturing, Inc. (Ontic), the aerospace industrys leading provider of Extended Life Solutions for Original Equipment Manufacturer (OEM) legacy products, has signed another new exclusive license agreement with Meggitt PLC for Pneumatic Valves, Digital Analogue Units (DAU), Triplex Transducer Units (TTU), Data Acquisition and Processing Units (DAPU) and Electronic Processing Units (EPU).
  • Under the terms of the agreement, Ontic will be responsible for all continuing Part 21 new build manufacturing, as well as comprehensive Part 145 repairs and spares support for the global customers.
  • Gareth Hall, President of Ontic, stated, Ontic and Meggitt have had a long standing partnership since 1995.
  • This is our 5th license agreement with Meggitt, and the latest in a recent succession of transactions.

Redfin Survey: Millennials Still Want Single-Family Homes, Even if it Means a Long Commute

Retrieved on: 
Thursday, November 21, 2019

The triplex is smaller, but meets your space needs, and has a shared backyard and significantly shorter commute.

Key Points: 
  • The triplex is smaller, but meets your space needs, and has a shared backyard and significantly shorter commute.
  • 89% of homebuyers would prefer a single-family home with a backyard over a unit in a triplex with a shorter commute.
  • Among millennials, 93% would choose a single-family home, as would the vast majority of all other age groups over 25.
  • The price premium for single-family homes over condos is declining in expensive areas and increasing in affordable inland areas.